AAAAAA

   
Results: 1-7 |
Results: 7
Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity
Authors: Adams, JL Boehm, JC Gallagher, TF Kassis, S Webb, EF Hall, R Sorenson, M Garigipati, R Griswold, DE Lee, JC
Citation: Jl. Adams et al., Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity, BIOORG MED, 11(21), 2001, pp. 2867-2870
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung
Authors: Underwood, DC Osborn, RR Bochnowicz, S Webb, EF Rieman, DJ Lee, JC Romanic, AM Adams, JL Hay, DWP Griswold, DE
Citation: Dc. Underwood et al., SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung, AM J P-LUNG, 279(5), 2000, pp. L895-L902
Nonpeptide tachykinin receptor antagonists. II. Ppharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potentand selective NK-3 receptor antagonist
Authors: Sarau, HM Griswold, DE Bush, B Potts, W Sandhu, P Lundberg, D Foley, JJ Schmidt, DB Webb, EF Martin, LD Legos, JJ Whitmore, RG Barone, FC Medhurst, AD Luttmann, MA Giardina, GAM Hay, DWP
Citation: Hm. Sarau et al., Nonpeptide tachykinin receptor antagonists. II. Ppharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potentand selective NK-3 receptor antagonist, J PHARM EXP, 295(1), 2000, pp. 373-381
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence
Authors: Underwood, DC Osborn, RR Kotzer, CJ Adams, JL Lee, JC Webb, EF Carpenter, DC Bochnowicz, S Thomas, HC Hay, DWP Griswold, DE
Citation: Dc. Underwood et al., SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence, J PHARM EXP, 293(1), 2000, pp. 281-288
Inhibition of contact sensitivity in human CD4(+) transgenic mice by humanCD4-specific monoclonal antibodies: CD4(+) T-cell depletion is not required
Authors: Podolin, PL Webb, EF Reddy, M Truneh, A Griswold, DE
Citation: Pl. Podolin et al., Inhibition of contact sensitivity in human CD4(+) transgenic mice by humanCD4-specific monoclonal antibodies: CD4(+) T-cell depletion is not required, IMMUNOLOGY, 99(2), 2000, pp. 287-295
In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity
Authors: Sarau, HM Foley, JJ Schmidt, DB Martin, LD Webb, EF Tzimas, MN Breton, JJ Chabot-Fletcher, M Underwood, DC Hay, DWP Kingsbury, WD Chambers, PA Pendrak, I Jakas, DR Sathe, GM Van Horn, S Daines, RA Griswold, DE
Citation: Hm. Sarau et al., In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity, PROS LEUK E, 61(1), 1999, pp. 55-64
Pyrimidinylimidazole inhibitors of CSBP/P37 kinase demonstrating decreasedinhibition of hepatic cytochrome P450 enzymes
Authors: Adams, JL Boehm, JC Kassis, S Gorycki, PD Webb, EF Hall, R Sorenson, M Lee, JC Ayrton, A Griswold, DE Gallagher, TF
Citation: Jl. Adams et al., Pyrimidinylimidazole inhibitors of CSBP/P37 kinase demonstrating decreasedinhibition of hepatic cytochrome P450 enzymes, BIOORG MED, 8(22), 1998, pp. 3111-3116
Risultati: 1-7 |